Characterization and Compatibility Studies of Different Rate Retardant Polymer Loaded Microspheres by Solvent Evaporation Technique: In Vitro-In Vivo Study of Vildagliptin as a Model Drug
Table 3
Average reduction in glucose level (mg/dL) in negative control, positive control, pure drug Vildagliptin, and formulation VF13.
Time (hour)
Average glucose level reduction (mg/dL)
Negative control (group I)
Positive control (group II)
Pure drug (group III)
Formulation VF13 (group IV)
0
70 ± 5.329
311.9 ± 5.92
361.44 ± 5.44
344.17 ± 7.49
1
70 ± 5.556
312.3 ± 4.36
205.82 ± 13.25
233.17 ± 8.68
2
70.1 ± 5.663
316.16 ± 7.77
157.7 ± 11.26
214.87 ± 7.71
3
70.2 ± 3.445
318.77 ± 8.67
137.4 ± 9.89
202.75 ± 8.21
4
70.25 ± 3.687
325.53 ± 11.26
110.08 ± 10.94
174.75 ± 5.94
5
70.29 ± 3.567
329.33 ± 3.77
119.98 ± 8.90
140.07 ± 4.67
6
70.3 ± 2.478
329.83 ± 4.78
139.96 ± 7.37
118.92 ± 3.32
7
70.3 ± 3.568
335.57 ± 10.57
162.32 ± 10.81
108.32 ± 3.70
8
70.31 ± 3.598
338.9 ± 11.93
186.14 ± 11.03
102.37 ± 4.68
12
71 ± 2.456
351.77 ± 12.06
237.56 ± 9.66
132.72 ± 5.19
24
71 ± 1.456
362.77 ± 7.39
307.68 ± 7.97
279.82 ± 6.05
48
71.2 ± 2.786
392.77 ± 7.40
317.68 ± 9.98
309.82 ± 8.06
Values are given as mean ± standard deviation for group of six rats.
